Veracyte Inc (NASDAQ:VCYT) Shares Bought by Boston Advisors LLC

Boston Advisors LLC lifted its stake in Veracyte Inc (NASDAQ:VCYT) by 114.1% in the third quarter, HoldingsChannel reports. The fund owned 54,066 shares of the biotechnology company’s stock after purchasing an additional 28,812 shares during the quarter. Boston Advisors LLC’s holdings in Veracyte were worth $1,298,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Tower Research Capital LLC TRC lifted its stake in shares of Veracyte by 1,433.3% in the 3rd quarter. Tower Research Capital LLC TRC now owns 1,150 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 1,075 shares during the period. Advisor Group Inc. acquired a new stake in shares of Veracyte during the second quarter valued at approximately $29,000. NumerixS Investment Technologies Inc acquired a new stake in shares of Veracyte during the second quarter valued at approximately $54,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Veracyte during the second quarter valued at approximately $78,000. Finally, US Bancorp DE raised its holdings in shares of Veracyte by 540.9% during the second quarter. US Bancorp DE now owns 2,916 shares of the biotechnology company’s stock valued at $83,000 after acquiring an additional 2,461 shares during the period.

Veracyte stock opened at $24.06 on Friday. The firm has a market cap of $1.15 billion, a PE ratio of -38.81 and a beta of 1.01. The firm’s 50 day moving average price is $23.77 and its two-hundred day moving average price is $25.51. Veracyte Inc has a twelve month low of $10.73 and a twelve month high of $31.18.

Veracyte (NASDAQ:VCYT) last released its quarterly earnings data on Tuesday, October 22nd. The biotechnology company reported ($0.02) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.07) by $0.05. The firm had revenue of $30.97 million for the quarter, compared to analyst estimates of $30.41 million. Veracyte had a negative net margin of 7.08% and a negative return on equity of 5.33%. Research analysts expect that Veracyte Inc will post -0.19 EPS for the current fiscal year.

VCYT has been the topic of a number of recent analyst reports. ValuEngine upgraded shares of Veracyte from a “sell” rating to a “hold” rating in a report on Thursday, October 31st. TheStreet upgraded shares of Veracyte from a “d” rating to a “c-” rating in a report on Thursday, August 1st. BidaskClub upgraded shares of Veracyte from a “hold” rating to a “buy” rating in a report on Thursday, November 7th. Lake Street Capital started coverage on shares of Veracyte in a research note on Wednesday, July 31st. They issued a “buy” rating and a $35.00 price objective on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $34.00 price objective on shares of Veracyte in a research note on Monday, October 28th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $25.46.

In related news, insider Giulia C. Kennedy sold 15,031 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $25.32, for a total transaction of $380,584.92. Following the completion of the sale, the insider now directly owns 51,787 shares of the company’s stock, valued at approximately $1,311,246.84. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Evan/ Fa Jones sold 10,000 shares of the company’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $26.11, for a total transaction of $261,100.00. Following the sale, the director now directly owns 25,000 shares of the company’s stock, valued at $652,750. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 76,958 shares of company stock worth $1,988,329. 8.30% of the stock is currently owned by company insiders.

About Veracyte

Veracyte, Inc operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis.

Further Reading: What are the benefits of a portfolio tracker?

Want to see what other hedge funds are holding VCYT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veracyte Inc (NASDAQ:VCYT).

Institutional Ownership by Quarter for Veracyte (NASDAQ:VCYT)

Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.